RSS   Newsletter   Contact   Advertise with us

AVEO Oncology appoints Matthew Dallas as CFO

Share on Twitter Share on LinkedIn
Staff Writer | Cambridge, Mass., USA | May 18, 2017
AVEO OncologyMay 18, 2017, Cambridge, Mass., USA - AVEO Oncology, a biopharmaceutical company, announced the appointment of Matthew Dallas as chief financial officer, effective June 1, 2017.
Mr. Dallas brings to AVEO more than 20 years of financial management experience, including 18 years in the life sciences industry.

Most recently, Mr. Dallas served as Chief Financial Officer and Treasurer of CoLucid Pharmaceuticals, a position he held through that biopharmaceutical company’s initial public offering, follow-on offering, and subsequent acquisition by Eli Lilly and Company in March 2017.

Prior to CoLucid, Mr. Dallas served as Vice President of Finance and Treasurer at AVEO from 2011 to 2015, a period during which the Company was first preparing for the potential launch of tivozanib.

Mr. Dallas previously worked at Genzyme Corporation, NEN Life Sciences, and Kimberly-Clark Corporation where he held various positions of increasing responsibility in finance and accounting.

He holds a B.S. in Finance from the University of Tennessee, Knoxville.


 LATEST MOVES FROM Massachusetts 


MORE INSIDE POST